Business Roundtable
Finance: An Opportunity That Shouldn't Be Missed - Recognizing Biotech Turnaround Investments
Wednesday, October 10, 2007
9:10 AM
Presidio
Investing in high-flying biotech companies comes with no guarantees. And failures or disappointments can slash market value by 25, 50 or even 75 percent. Within these tragic short-term setbacks lie reduced risk investments if you consider your basis and the opportunity to pursue a new investment thesis. How do you determine the value of the remaining assets or see the gems in the ashes? How do you gauge the move-forward strategy and management's ability to execute? Learn from the investors who seek out these companies and the executives who have seen the bottom and lived to tell their story. Discussion will also address recent case studies on the performance of biotech blow-ups and the impressive turnarounds that have rewarded new investors.
Moderators
- Rahul Jasuja, PhD; Managing Director, Life Sciences Research, MDB Capital Group LLC
Panelists
- Selena Chaisson, MD; Director of Healthcare Investments, Bailard, Inc.
- Robert W. Karr, MD; President, Idera Pharmaceuticals, Inc.
- Jerry McMahon, PhD; Chairman and Chief Executive Officer, Poniard Pharmaceuticals, Inc.
- Oleg Nodelman; Portfolio Manager, Biotechnology Value Fund, L.P.
- Vinny R. Jindal; Principal, Boston Millennia Partners
Who's Who
Mr. Jasuja joined MDB Capital Group in 2004 to lead its life sciences research effort, bringing both a medical background as well as extensive institutional equity research experience. Prior to joining MDB Capital Group, Mr. Jasuja served as Senior Biotechnology Research Analyst SOMA Partners LLC (formerly Techvest, LLC) and Sagient Research Systems. His past experience includes positions as Senior Biotechnology Research Analyst for the New York investment banking firm of Rodman & Renshaw. He has conducted equity research, due-diligence and consulting for institutional investors in a wide range of areas in molecular medicine, including immunotherapy, autoimmunity/inflammation, metabolic diseases, oncology, cardiology, ophthalmology, regenerative medicine and tissue engineering. Mr. Jasuja received his scientific training in immunology at Tufts Medical School and Harvard Medical School. He has conducted research in the areas of cell signaling, cancer biology, T-lymphocyte adhesion and activation, and macrophage arachidonic acid metabolism. At Tufts Medical School, he taught and supervised medical and dental students in the field of immunology. Mr. Jasuja received his B.Sc. from St. Xavier?s College, Bombay (India), his M.S. in Microbiology & Molecular Biology from the University of Montana and his Ph.D. in Immunology from Tufts Medical School in Boston.